Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as crucial agents not only for glycemic control but also for their broad cardiovascular protective effects, particularly in individuals with CAD [8,9]. The gene discussed is SLC5A2; the disease is coronary artery disorder.